Clavis Pharma Taps Skyline Dx for Array-based Patient Selection in AML Drug Trial | GenomeWeb

By Justin Petrone

Snagging its second companion diagnostics deal in as many months, Skyline Diagnostics this week announced a research agreement with Clavis Pharma to assist the Norwegian pharmaceutical company in the development of a drug for acute myeloid leukemia.

Skyline CEO Henk Vietor told BioArray News that Skyline will use Affymetrix-manufactured arrays to identify gene-expression biomarkers for the selection of individual AML patients that may benefit from Clavis' compound.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.